Cancer Variant Interpretation Group UK (CanVIG-UK): updates on an exemplar national subspecialty multidisciplinary network
Alice GarrettiD, Sophie AlleniD, Charlie F RowlandsiD, Subin ChoiiD, Miranda DurkieiD, George J. BurgheliD, Rachel RobinsoniD, Alison CallawayiD, Joanne Field, Bethan A. Frugtniet, Sheila Palmer-Smith, Jonathan GrantiD, Judith Pagan, Trudi McDevittiD, L. Hughes, Elizabeth Johnston, Laura Yarram-SmithiD, Peter Logan, Laura Reed, Katie M.G. SnapeiD, Helen HansoniD, Terri Patricia McVeighiD, Clare TurnbulliD, CanVIG-UK
Abstract
Cancer Variant Interpretation Group UK was established in 2017 in response to the publication of the 2015 ACMG/AMP v3 guidance for the interpretation of sequence variants. Its initial purpose was to ensure consistency in the UK clinical-laboratory community implementation of ACMG/AMP v3 guidance for cancer susceptibility genes (CSGs). Still convening for monthly national meetings, the remit of CanVIG-UK now encompasses additional activities delivered under the following objectives: O_LICreation of a national multidisciplinary professional network and regular forum. C_LIO_LIDelivery of training and education. C_LIO_LIEstablishment of a consensus approach to the fundamentals of variant interpretation in cancer susceptibility genes. C_LIO_LIDevelopment and ratification of gene-specific frameworks for variant interpretation for cancer susceptibility genes. C_LIO_LIDevelopment and maintenance of an online platform to facilitate information sharing and variant interpretation within the UK clinical-laboratory community. C_LIO_LIFacilitation of UK contribution to international variant interpretation endeavours. C_LI A survey of CanVIG-UK members evaluating the impact of these activities conducted in November 2025 had 163 responses, including 113 clinical scientists/trainees and 27 Clinical Genetics consultants/trainees. The utility of the CanVIG-UK consensus recommendations for variant interpretation in cancer susceptibility genes was highly rated, with 89/145=61.4% of survey respondents reporting using the guidance at least weekly ([≥]4 times/month) and 124/128=96.9% rating it as extremely/very useful. The usage frequency and utility of the gene-specific guidance reported by survey respondents were similar to those reported for the main consensus specification. Both qualitative and quantitative survey responses clearly demonstrate the value of the CanVIG-UK activities to the clinical-diagnostic community. Key messagesO_LIWhat is already known on this topic: Cancer Variant Interpretation Group UK (CanVIG-UK) is a national subspeciality multidisciplinary network first established in 2017. It brings together members of the UK clinical-laboratory community to improve accuracy and consistency in the interpretation of variants in cancer susceptibility genes (CSG) C_LIO_LIWhat this study adds: this article presents the results of a survey of CanVIG-UK members, demonstrating the impact of CanVIG-UK activities on their services, as well as a review of progress in the six updated objectives of CanVIG-UK C_LIO_LIHow this study might affect research, practice or policy: this article presents current priorities and practices and potential future directions for variant interpretation in CSGs across the UK and Republic of Ireland C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 4.05
- Field percentile
- top 6%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CanVar-UK: an online data platform supporting collaborative diagnostic interpretation of germline variants in cancer susceptibility genes
Charlie F Rowlands, Subin Choi, … CanVIG-UK·medRxiv·Mar 25, 2026
- Classification of Variants of Reduced Penetrance in High Penetrance Cancer Susceptibility Genes: Framework for Genetics Clinicians and Clinical Scientists by CanVIG-UK (Cancer Variant Interpretation Group-UK)
Alice Garrett, Sophie Allen, … J. Williams·Genetics in MedicinePeer-reviewed·Oct 24, 2024
- Cancer SIGVAR: A semi-automated interpretation tool for germline variants of hereditary cancer-related genes
Hong Li, Shuixia Liu, … Yun Xiong·Human MutationPeer-reviewed·Feb 10, 2021
- Evolution of the open-access CIViC knowledgebase is driven by the needsof the cancer variant interpretation community
Kilannin Krysiak, Arpad M. Danos, … Malachi Griffith·bioRxiv·Jun 13, 2021
- The CIViC knowledge model and standard operating procedures for curation and clinical interpretation of variants in cancer
Arpad M. Danos, Kilannin Krysiak, … Obi L. Griffith·Genome MedicinePeer-reviewed·Nov 28, 2019
- CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer.
Malachi Griffith, Nicholas C Spies, … Elaine R Mardis·bioRxiv·Sep 1, 2016